Souhaitez-vous accéder aux communiqués récents ?

Argobio successfully facilitated fundraising and syndication process, following its earlier role in creating and pre-seed funding Enodia Financing co-led by Elaia, Pfizer Ventures and BpifranceEnodia...

Dublin, Jan. 08, 2026 (GLOBE NEWSWIRE) -- The "Biomimetic Plastic Material Market in Saudi Arabia" has been added to ResearchAndMarkets.com's offering. The global biomimetic plastic material...

MannKind Provides Business Updates and 2026 Growth Drivers

KUALA LUMPUR, Malaysia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (NASDAQ: ALPS) (the “Company” or “Alps Group”), a fully integrated biotechnology research and healthcare platform...

Financing supports Phase 2 development of ALV-100, IND filing of ALV-200 and advancement of additional programs across the R&D pipeline ALV-100, a bifunctional GIPR antagonist / GLP-1R agonist,...

AtaiBeckley provides its outlook for 2026 ahead of attendance at the J.P. Morgan 44th Annual Healthcare Conference

Freiburg im Breisgau, Germany – January 8, 2026 – Eleva, a pioneer in discovering and developing previously inaccessible biologics, today announced the appointment of Dr. Erich Rajkovic, MBA, as Chief...

BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

Avance Clinical Strengthens Global Oncology Offering with Acquisition of U.S.-Based LumaBridge and Establishes New Oncology Center of Excellence.

BBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month progression-free survival (PFS), with 83% of patients...